Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Can only think this shall be good for us: - tomato juice is an acquired taste
https://www.tomatofoundation.org/project_pf_results
https://www.tomatonews.com/en/can-tomato-juice-prevent-blood-clots_2_1826.html
W$
It does make one wonder how much it costs to set up a plant to make FF
Throw in transportation overhead (ESG/$), it does make the case of in country manufacturing very compelling and a bleedin obvious next step after things settle down (step change in cashflow) next year.
W$
Thx for offer Kievs, I'm down you way early next month so we should meet up for a mulled wine. Sounds like the AGM was worth going to after all !!!
alf, I read it as Gretna police and thought how does he know that ?
Bleedin obvious, if it were we wouldn't being have this conversation.
BTW, according to Peng He's slides the cost of tomatoes in China is significantly lower than California and EUs. Suspect another deal with BH to share this saving.
https://www.tomatonews.com/en/the-2022-tomato-news-conference-slides_2_1809.html
W$
This popped up a few days ago. Looks like they are jumping on the FF antiplatelet bandwagon.
https://journals.sagepub.com/doi/abs/10.1177/02601060221135334
Development of the whole tomato and olive-based food supplement enriched with anti-platelet aggregating nutrients
Abstract
Background
Platelet dysfunctions are shared by cardiovascular diseases and a wide range of inflammatory diseases.
Aims
To determine the ability of a new whole tomato-based food supplement (WTBFS) containing carotenoid and olive polyphenols to inhibit platelet aggregation.
Methods
Aggregation was evaluated in platelet-rich plasma using microtiter plates and a plate reader.
It's behind a pay wall, but uses three of our publications as references.
O’Kennedy N, Crosbie L, Song HJ, et al. (2017) A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract fruitflow, with 75?mg aspirin in healthy subjects. European Journal of Clinical Nutrition 71(6): 723–730.
O’Kennedy N, Duss R, Duttaroy AK (2021) Dietary antiplatelets: A new perspective on the health benefits of the water-soluble tomato concentrate fruitflow. Nutrients 13(7): 2184.
O’Kennedy N, Duttaroy AK (2021) Platelet hyperactivity in COVID-19: Can the tomato extract fruitflow® be used as an antiplatelet regime? Medical Hypotheses 147: 110480.
What is interesting is the authors from from very medical sounding establishments
Department of Experimental Medicine, La Sapienza University of Rome, Rome, Italy
Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, G. d’Annunzio University, Chieti, Italy
CREA Laboratory (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
Kievsky
Good to see you made in back from the smoke in one piece !!
W$
I would hope all the research, patents, and supply chain mean IF et al shall be pushing against multiple new open doors after Jan.
Good to see no share action after the AGM, perhaps next year IF should give an option to dial in....
W$
Thx Gixer
it is easy to forget what a big deal getting BlueCap would be.
I appreciate the snippets that those who make the effort to attend to AGM kindly share with us. It's not a cheap day out these days, could probably buy a few million shares at current SP for the cost of it!!
W$
So Frederic is leaving DSM 3 months b4 the new PXS world order - could be a coincidence but a 3 months is probably his notice period. He shall be privvy to everything (multiple sales, funnels, etc blah blah) and I'm sure a small company like us could tempt him with lucrative stock options (big corps don't offer potential for jackpots - the DSM shares are heading south fast so his LTIPS might be worth jack atm) that might have value if what IF has been dangling in front of us is not just BS. Alternatively, what about BH, presumably he has been working closely with them ?
As good a conspiracy theory as any atm.....
W$
DP
what is clear is that FF+ income tracked income from DSM PSA. So it looks like FF+ sales have been restricted by general FF availability to DSM (not sure what happened in 2021). With the planned supply increases .............
https://postimg.cc/68MN1XjR
W?
Nothing we don't already know. I've added FF+ revenue
https://postimg.cc/ctdzMK1T
Takeaways
launching FF+ has been a good move, extra cash it brings is very useful income
if research were stopped we would have been in profit.
If no covid issues DSM PSA should have been nearer 500K and hence losses less than 50K.
With new deal the "DSM PSA" should multiply and we should be in good profit (once issue with supply chain costs/stock settles).
( two million users at 2p profit to us per dose puts us worth 5 to 10p a share and IF stock options become very valuable)
W$
Looking forward to what area IF plans to focus on.
https://twitter.com/FruitflowPlus
https://www.forbes.com/sites/marijabutkovic/2022/09/30/whats-next-for-female-cardiovascular-health-4-industry-experts-weigh-in/?sh=1580285775e0
W$